Quantbot Technologies LP Decreases Holdings in DaVita Inc. $DVA

Quantbot Technologies LP trimmed its stake in DaVita Inc. (NYSE:DVA) by 46.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,165 shares of the company’s stock after selling 25,546 shares during the quarter. Quantbot Technologies LP’s holdings in DaVita were worth $3,875,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. NewEdge Advisors LLC raised its stake in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the period. Goldman Sachs Group Inc. increased its holdings in DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after acquiring an additional 28,739 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in DaVita in the 2nd quarter valued at about $1,243,000. Teacher Retirement System of Texas lifted its holdings in DaVita by 1.4% during the second quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock valued at $954,000 after purchasing an additional 94 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its position in DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DVA stock opened at $156.28 on Monday. The company has a market capitalization of $10.44 billion, a PE ratio of 15.77, a price-to-earnings-growth ratio of 0.55 and a beta of 0.93. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $157.91. The business’s fifty day moving average is $124.18 and its 200 day moving average is $125.91.

DaVita (NYSE:DVA) last announced its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period in the prior year, the company earned $2.24 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Truist Financial set a $158.00 price target on DaVita in a research report on Thursday, February 5th. UBS Group increased their price objective on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Finally, Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $155.80.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.